IP Library Granted Patent US 9,776,985
Granted Patent B2
US 9,776,985 · App. 14/893,620 · Granted Oct 3, 2017

Process for preparation of alogliptin

Inventors: Navin Ganesh Bhatt (Navi Mumbai, IN); Samir Naik (Thane, IN); Ajay Kumar Sharma (Pardesh, IN); Mahendra Joma Choraghe (Navi Mumbai, IN); Shekhar Bhaskar Bhirud (Mumbai, IN)
Assignee: GLENMARK PHARMACEUTICALS LIMITED
C07D401/04C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,776,985
App. No.
14/893,620
Granted
Oct 3, 2017
Kind
B2
Abstract

Provided is a novel process for the preparation of alogliptin.

Claims (21)

1. A process for the preparation of alogliptin, a compound of formula I, or a salt thereof, comprising:

a) methylating a compound of formula IV, to obtain a compound of formula V

wherein R 1 and R 2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is unsubstituted or substituted with one or more R 3 substituents selected from the group consisting of halogen, alkyl, nitro and amino; and

b) deprotecting the compound of formula V to obtain compound of formula I.

2. The process of claim 1 , wherein R 1 and R 2 together with the nitrogen to which they are attached form a phthalimido group and wherein R 3 on the aromatic ring of the phthalimido group is alkyl.

3. The process of claim 2 , wherein the deprotection is carried out in presence of an amine.

4. A compound of formula IV having a purity of 90 to 95%:

wherein R 1 and R 2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is substituted with one or more R 3 substituents selected from the group consisting of halogen, alkyl, nitro and amino.

5. The compound of claim 4 , wherein R 1 and R 2 together with the nitrogen to which they are attached form a phthalimido group and wherein R 3 on the aromatic ring of the phthalimido group is alkyl.

6. The compound of claim 5 , wherein R 1 and R 2 together with the nitrogen to which they are attached form a phthalimido group and wherein R 3 on the aromatic ring of the phthalimido group is methyl, represented by compound of Formula Iva

7. The process of claim 1 , wherein the compound of formula IV is prepared by a process comprising

reacting a compound of formula II with a compound of formula III

wherein R 1 and R 2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is unsubstituted or substituted with one or more R 3 substituents selected from the group consisting of halogen, alkyl, nitro and amino.

8. A compound of Formula Va having a purity more than 99%:

9. The process of claim 1 , further comprising;

(a) treating alogliptin with an acid to form an acid addition salt of alogliptin; and

(b) treating the acid addition salt of alogliptin with a base followed by addition of benzoic acid to obtain alogliptin benzoate.

10. The process of claim 9 , further comprising isolating alogliptin benzoate from a solvent selected from the group consisting of n-propanol, hexane, ethylene dichloride, methyl tertiary butyl ether, xylene, methyl tetrahydrofuran, propyl acetate, methyl acetate or mixtures thereof.

11. The process of claim 10 , wherein the step of isolating comprises

a) subjecting alogliptin benzoate to slurrying in a solvent selected from the group consisting of n-propanol, hexane, ethylene dichloride, methyl tertiary butyl ether, xylene, methyl tetrahydrofuran, propyl acetate, methyl acetate or mixtures thereof to obtain solid alogliptin benzoate; and

b) filtering out the solid alogliptin benzoate, obtained in step a.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2017
From: BHATT, NAVIN GANESH; NAIK, SAMIR; SHARMA, AJAY KUMAR; CHORAGHE, MAHENDRA JOMA; BHIRUD, SHEKHAR BHASKAR
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 040868/0535 →
Priority Claims (1)
IN 1844/MUM/2013 · May 24, 2013 · national
Continuity (1)
Related Publication 20160340333A1 · Nov 24, 2016